Diabetic macular oedema
The PBS subsidises ranibizumab, aflibercept and dexamethasone intravitreal implants for patients with visual impairment due to diabetic macular oedema (DMO).
Patients must be treated by an ophthalmologist to be eligible for PBS subsidised treatment with these medications.
The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing ranibizumab, aflibercept and dexamethasone intravitreal implant to patients.
Authority approval for initial treatment of each eye is required.
The first authority application for each eye must be made in writing.
After an application for initial treatment is approved, applications for continuing treatment in the same eye or eyes may be made in writing or by phone.
All applications for ranibizumab and aflibercept may be for the initial treatment and up to 5 repeats. Where both eyes are being treated simultaneously, a quantity of 2 may be requested on the same prescription.
Patients must meet the relevant criteria as indicated in the PBS restrictions and be eligible for the PBS.
Lodging an application
Written applications for initial approval must include a:
- completed authority prescription form
- completed Diabetic Macular Oedema Initial PBS authority application Supporting information form (PB155), and
- copy of the diagnostic optical coherence tomography or fluorescein angiography report
Send all written applications to the PBS Complex Drugs Programs address.
Emergency treatments only
To avoid a delay in starting treatment, phone applications for initial approval can be made. The completed application form and authority prescription form must be faxed to the PBS Complex Drugs Programs team, who will contact the prescriber by phone to discuss. You must then send the original application form and a copy of the optical coherence tomography or fluorescein angiography to the PBS Complex Drugs Programs address.
For more information contact the PBS Complex Drugs Programs enquiry line.